GPT Healthcare quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	126	107	+17.8%
EBITDA	24.2	17.4	+39.3%
EBITDA margin	19.2%	16.2%	+2.9 pts
Profit before tax	17.2	11.1	+54.4%
Net profit	12.7	7.7	+65.7%
EPS	₹1.55	₹0.94	+64.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023

Expenses
	126	126	120	119	107	101	102	106	97.8	99.4	96.6
	2.0	1.6	1.4	1.3	1.6	1.6	1.9	2.8	2.2	1.6	1.2
	128	128	122	120	109	103	104	108	100	101	97.8
	24.1	23.4	23.5	22.2	20.7	20.0	20.2	20.3	18.3	20.8	19.7
	23.2	22.2	21.4	20.3	20.4	18.1	18.5	17.7	18.7	17.0	17.3
	2.2	2.2	2.3	2.2	1.6	1.0	0.9	0.7	0.9	1.6	1.7
	6.9	6.9	7.1	6.8	6.2	4.9	4.7	4.8	4.7	4.8	4.5
	54.6	57.4	54.5	53.7	48.7	42.7	42.3	44.2	42.8	38.5	38.6
	111	112	109	105	97.6	86.6	86.5	87.8	85.4	82.6	81.8
	24.2	23.4	20.7	22.7	17.4	20.7	21.3	23.4	18.0	23.2	21.0
	17.3	16.4	13.6	15.9	11.2	15.8	16.6	18.6	13.3	18.4	16.5
Profit
	17.2	15.9	12.8	15.1	11.1	16.4	17.6	20.7	14.7	18.4	16.0
	17.2	15.9	12.8	15.1	11.1	16.4	17.6	20.7	14.7	18.4	16.0
	4.7	4.8	3.3	2.5	2.0	2.7	3.1	3.7	2.6	3.2	2.8
	−0.3	−3.5	0.1	2.0	1.4	0.8	2.2	2.2	2.1	2.4	1.7
	4.4	1.3	3.4	4.5	3.4	3.5	5.4	5.9	4.7	5.6	4.5
	12.7	14.6	9.4	10.6	7.7	12.9	12.2	14.8	10.0	12.8	11.5
	12.7	14.6	9.4	10.6	7.7	12.9	12.2	14.8	10.0	12.8	11.5
	−0.0	−0.1	−0.0	−0.0	−0.0	0.2	−0.2	0.0	0.0	0.3	−0.1
	12.7	14.5	9.4	10.6	7.7	13.1	12.0	14.8	10.0	13.1	11.4
Per share
	₹1.55	₹1.78	₹1.14	₹1.29	₹0.94	₹1.57	₹1.49	₹1.81	₹1.21	₹1.59	₹1.44
	₹1.55	₹1.78	₹1.14	₹1.29	₹0.94	₹1.57	₹1.49	₹1.81	₹1.21	₹1.59	₹1.44
Other comprehensive income — detail
	−0.0	−0.1	−0.0	−0.0	−0.0	0.2	—	—	—	—	—
	—	−0.1	−0.0	−0.0	—	0.3	−0.3	—	0.0	0.4	−0.1
	—	−0.0	−0.0	−0.0	—	0.1	—	—	—	—	—
	—	—	—	—	—	—	−0.1	—	0.0	0.1	−0.0
	−0.0	—	—	—	−0.0	—	—	0.0	—	—	—
	−0.0	0.0	0.0	0.0	−0.0	0.0	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	0.0	0.0	0.0
Per share — as-filed variants
	₹1.55	₹1.78	₹1.14	₹1.29	₹0.94	₹1.57	₹1.49	₹1.81	₹1.21	₹1.59	₹1.44
	₹1.55	₹1.78	₹1.14	₹1.29	₹0.94	₹1.57	₹1.49	₹1.81	₹1.21	₹1.59	₹1.44
Regulatory disclosures — filed alongside, not part of the P&L
	—	13.2	—	15.1	—	13.5	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	102	103	96.6	96.7	86.4	81.4	82.0	85.3	79.5	78.6	76.9
	80.9%	81.5%	80.4%	81.3%	80.7%	80.3%	80.3%	80.8%	81.2%	79.1%	79.6%
Adjusted (ex-exceptional items) — derived
	17.2	15.9	12.8	15.1	11.1	16.4	17.6	20.7	14.7	18.4	16.0
	12.7	14.6	9.4	10.6	7.7	12.9	12.2	14.8	10.0	12.8	11.5
	₹1.55	₹1.78	₹1.14	₹1.29	₹0.94	₹1.57	₹1.49	₹1.81	₹1.21	₹1.59	₹1.44

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

GPTHEALTH₹132.20

GPT Healthcare Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersGKSL SHALBY INDRAMEDCO LOTUSEYE ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹1,085 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	96.6	99.4	97.8	105.7	102.2	101.4	107.1	118.9	120.2	126.4	126.2
Other Income	1.2	1.6	2.2	2.8	1.9	1.6	1.6	1.3	1.4	1.6	2.0
Total Income	97.8	101.0	100.1	108.5	104.1	103.0	108.7	120.2	121.6	128.0	128.2
Expenses
+ Cost of Materials Consumed	19.7	20.8	18.3	20.3	20.2	20.0	20.7	22.2	23.5	23.4	24.1
+ Employee Benefit Expense	17.3	17.0	18.7	17.7	18.5	18.1	20.4	20.3	21.4	22.2	23.2
+ Finance Costs	1.7	1.6	0.9	0.7	0.9	1.0	1.6	2.2	2.3	2.2	2.2
+ Depreciation & Amortisation	4.5	4.8	4.7	4.8	4.7	4.9	6.2	6.8	7.1	6.9	6.9
+ Other Expenses	38.6	38.5	42.8	44.2	42.3	42.7	48.7	53.7	54.5	57.4	54.6
Total Expenses	81.8	82.6	85.4	87.8	86.5	86.6	97.6	105.2	108.8	112.1	111.1
EBITDA	21.0	23.2	18.0	23.4	21.3	20.7	17.4	22.7	20.7	23.4	24.2
EBIT	16.5	18.4	13.3	18.6	16.6	15.8	11.2	15.9	13.6	16.4	17.3
Profit
PBT before Exceptional Items	16.0	18.4	14.7	20.7	17.6	16.4	11.1	15.1	12.8	15.9	17.2
Pretax Income	16.0	18.4	14.7	20.7	17.6	16.4	11.1	15.1	12.8	15.9	17.2
+ Current Tax	2.8	3.2	2.6	3.7	3.1	2.7	2.0	2.5	3.3	4.8	4.7
+ Deferred Tax	1.7	2.4	2.1	2.2	2.2	0.8	1.4	2.0	0.1	-3.5	-0.3
Tax Expense	4.5	5.6	4.7	5.9	5.4	3.5	3.4	4.5	3.4	1.3	4.4
Net Income	11.5	12.8	10.0	14.8	12.2	12.9	7.7	10.6	9.4	14.6	12.7
+ Net Income — Continuing Ops	11.5	12.8	10.0	14.8	12.2	12.9	7.7	10.6	9.4	14.6	12.7
+ Other Comprehensive Income	-0.1	0.3	0.0	0.0	-0.2	0.2	-0.0	-0.0	-0.0	-0.1	-0.0
Total Comprehensive Income	11.4	13.1	10.0	14.8	12.0	13.1	7.7	10.6	9.4	14.5	12.7
Per Share
Basic EPS	1.44	1.59	1.21	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55
Diluted EPS	1.44	1.59	1.21	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	0.2	-0.0	-0.0	-0.0	-0.1	-0.0
+ Items NOT to be Reclassified to P&L	-0.1	0.4	0.0	—	-0.3	0.3	—	-0.0	-0.0	-0.1	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.1	—	-0.0	-0.0	-0.0	—
+ Tax on Items NOT to be Reclassified — alt tag	-0.0	0.1	0.0	—	-0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	0.0	—	—	-0.0	—	—	—	-0.0
+ Tax on Items to be Reclassified	—	—	—	—	—	0.0	-0.0	0.0	0.0	0.0	-0.0
+ Tax on Items to be Reclassified — alt tag	0.0	0.0	0.0	0.0	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.44	1.59	1.21	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55
Diluted EPS — Continuing Operations	1.44	1.59	1.21	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	13.5	—	15.1	—	13.2	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	76.9	78.6	79.5	85.3	82.0	81.4	86.4	96.7	96.6	103.0	102.1
Gross Margin %	79.61	79.09	81.25	80.77	80.26	80.32	80.70	81.34	80.42	81.48	80.87
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	16.0	18.4	14.7	20.7	17.6	16.4	11.1	15.1	12.8	15.9	17.2
Net Income Adj (tax-effected)	11.5	12.8	10.0	14.8	12.2	12.9	7.7	10.6	9.4	14.6	12.7
EPS Adj	1.44	1.59	1.21	1.81	1.49	1.57	0.94	1.29	1.14	1.78	1.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	8.0	82.1	82.1	82.1	82.1	82.1	82.1	82.1	82.1	82.1	82.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

GPT Healthcare Q2 FY27 results date

GPT Healthcare (NSE: GPTHEALTH) will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, according to the board-meeting notice it filed on 27 October 2026, which also lists a dividend. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹12.7 crore, up 65.7% from ₹7.7 crore in Q1 FY26 and down 12.6% from ₹14.6 crore in Q4 FY26. Revenue from operations was ₹126 crore, up 17.8% year on year and down 0.1% from the previous quarter.

Board-meeting notice filed: 27 October 2026
Q2 FY26 results (a year earlier): 8 November 2025
Q1 FY27 results (the latest): 3 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 5 November 2026Thursday · notice filed 27 Oct
Q1 FY27 net profit: ₹12.7 Cr+65.7% vs Q1 FY26−12.6% vs Q4 FY26
Q1 FY27 revenue: ₹126 Cr+17.8% vs Q1 FY26−0.1% vs Q4 FY26
Q1 FY27 operating margin: 13.7%+3.3 pts vs Q1 FY26+0.7 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹10.6 CrRevenue ₹119 Cr
Q1 FY27 EPS (basic): ₹1.55

Questions

When will GPT Healthcare announce its Q2 FY27 results?

On 5 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 27 October 2026). Last year it reported Q2 FY26 on 8 November 2025.

What will GPT Healthcare's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹10.6 crore and revenue from operations ₹119 crore. The latest quarter, Q1 FY27, had a net profit of ₹12.7 crore and revenue of ₹126 crore.

What were GPT Healthcare's Q1 FY27 results?

Consolidated net profit was ₹12.7 crore, up 65.7% from ₹7.7 crore in Q1 FY26 and down 12.6% from ₹14.6 crore in Q4 FY26. Revenue from operations was ₹126 crore, up 17.8% year on year and down 0.1% from the previous quarter.

How has GPT Healthcare's profit changed over the last four quarters?

Net profit by quarter: ₹10.6 crore in Q2 FY26, ₹9.4 crore in Q3 FY26, ₹14.6 crore in Q4 FY26 and ₹12.7 crore in Q1 FY27. That is ₹47.3 crore over the four quarters, down 0.8% from ₹47.6 crore in the four quarters before. Revenue from operations: ₹119 crore, ₹120 crore, ₹126 crore and ₹126 crore.

What was GPT Healthcare's net profit in FY26?

Consolidated net profit was ₹42.2 crore in FY26 (April 2025–March 2026), down 15.4% from ₹49.9 crore in FY25. It was ₹47.8 crore in FY24.

What was GPT Healthcare's revenue in FY26?

Revenue from operations was ₹473 crore in FY26 (April 2025–March 2026), up 16.1% from ₹407 crore in FY25. It was ₹400 crore in FY24.

Where do these GPT Healthcare figures come from?

From GPT Healthcare's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.